Navigation Links
EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Date:10/2/2008

ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has received approval from the Nasdaq Listing Qualifications Department to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer will become effective as of the opening of the market on Friday, October 3, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Nasdaq Global Select Market, the Nasdaq Global Market, and the Nasdaq Capital Market are the three market tier designations for companies listed on the Nasdaq. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market. EntreMed's trading symbol will remain "ENMD" and trading of the Company's stock will be unaffected by this change. Securities listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards.

The Company's decision to transfer to the Nasdaq Capital Market is in response to a letter dated April 4, 2008 from the Nasdaq Stock Market, LLC notifying the Company that its common stock failed to close above the minimum closing bid price of $1.00 per share for 30 consecutive business days, which is required for listing on the Nasdaq Global Market. Transfer to the Nasdaq Capital Market extends the requirement to achieve a minimum $1.00 bid price until March 30, 2009.

James S. Burns, President and Chief Executive Officer, commented, "We have sufficient capital to advance our
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. ... H. Anderson , president and chief executive officer, will ... Wednesday, September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may ... webcast will be available shortly after conclusion of the ...
(Date:9/2/2015)... , September 2, 2015 ... Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben zu ... vom Rare Genomics Institute. Biovista unterstützt ... Medikamenten für die Behandlung anderer Krankheiten als denen, ... Steven Laffoon und sein Team bei der ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... will improve efficiency of their entire waste to energy process and continue to ... Gets a Major Upgrade , Temarry’s Waste to Energy process has been operating ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... ... distribute feedstock for E-Fuel MicroFueler™ , ... Sacramento (Vocus) June 4, 2009 -- California Governor Arnold Schwarzenegger joined ... Corp. unveiled the final production model of the revolutionary E-Fuel MicroFueler, a portable micro-refinery ...
... WEBCAST WEDNESDAY, JUNE 10, 2009 , , SAN ... NBIX ) announced today that Kevin Gorman, President and Chief ... 8th Annual Needham Life Sciences Conference in New York. ... 10, 2009 at 1:30 p.m. Eastern Time (ET)/10:30 a.m. Pacific ...
... , BRAINTREE, Mass., June 4 Haemonetics Corporation (NYSE: ... for the District of Massachusetts has made a ruling in ... January 2009, a jury issued a verdict in favor of ... a U.S. Haemonetics patent. The jury awarded Haemonetics $15.7 ...
Cached Biology Technology:GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California 2GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California 3Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference 2Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology 2
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... at Iowa State University have discovered a previously unknown ... Yanhai Yin, an assistant professor in genetics, development and ... called brassinosteroids. The hormone controls the growth of cells. ... how large the plant grows, says Yin. , "Previously, ...
... the oldest synthetic malaria drug, the methylene blue stain, ... a significant contribution to the long-term eradication called for ... study on 160 children with malaria in Burkina Faso, ... have shown that in combination with newer malaria drugs, ...
... Some researchers hope to turn plants into a renewable, ... have to learn how to convert plant biomass into ... efficiently. In new research, chemists have successfully converted cellulose ... the building block called HMF in one step. ...
Cached Biology News:ISU researcher identifies genetic pathway responsible for much of plant growth 2Old stain in a new combination 2Old stain in a new combination 3Plastic that grows on trees, part two 2
...
... For amplification of GC-rich nucleic acids ... Taq DNA Polymerase and a proofreading polymerase, ... impossible to amplify with other polymerases and ... of the blend and the unique GC-RICH ...
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
... nucleofection of optimized cell lines in combination ... nucleofection parameters. Nucleofector Kits are only functional ... cell lines can be transfected with this ... given in brackets in percent (Efficiency [%] ...
Biology Products: